Patients with sickle cell disease (SCD) display priapism, a prolonged penile erection in the
absence of sexual arousal. The current pharmacological treatments for SCD-associated …

Importance of the field: Erectile dysfunction (ED) is the most common male sexual
dysfunction presented for treatment affecting between 10 and 20% of men. PDE type 5 …

Erectile dysfunction (ED) affects up to 50% of men between the ages of 40 and 70.
Treatment with PDE‐5 inhibitors is effective in the majority of men with ED. However, PDE‐5 …

Nitric oxide (NO) is the principal mediator of penile erection, and soluble guanylate cyclase
(sGC) is the receptor for NO. In pathophysiological conditions when sGC is inactivated and …

Introduction Overall efficacy rates of phosphodiesterase type 5 inhibitors (PDE5‐i) for
erectile dysfunction (ED) are 60–70%. PDE5‐i treatment failures currently have to resort to …

Introduction Cardiovascular and endocrine-metabolic diseases associated with increased
oxidative stress such as obesity lead to erectile dysfunction (ED). Activators of soluble …

Objectives To evaluate the expression of the Rho/Rho‐associated protein kinase (ROCK)
pathway in the corpus cavernosum of patients with severe erectile dysfunction (ED) …

Priapism, defined as a prolonged and often painful penile erection occurring without sexual
stimulation or desire, is a common complication in sickle cell disease (SCD), affecting up to …

In recent years, research on penile erection has increasingly been centered on the
molecular mechanisms involved. Major progress has been made in the field and at present …

Introduction The nitric oxide (NO), soluble guanylate cyclase (sGC), and cyclic guanosine
monophosphate (cGMP) pathway is the leading pathway in penile erection. Aim To assess …